医学
贝伐单抗
化疗
危险系数
软组织肉瘤
横纹肌肉瘤
内科学
外科
环磷酰胺
肉瘤
肿瘤科
置信区间
软组织
病理
作者
Julia Chisholm,Johannes H. M. Merks,Michela Casanova,Gianni Bisogno,Daniel Orbach,Jean Claude Gentet,Anne‐Sophie Defachelles,Pascal Chastagner,Stephen P. Lowis,Milind Ronghe,Kieran McHugh,Rick R. van Rijn,Magalie Hilton,Jeanette Bachir,Sabine Fürst‐Recktenwald,Birgit Geoerger,Odile Oberlin
标识
DOI:10.1016/j.ejca.2017.06.015
摘要
Purpose We evaluated the role of bevacizumab as part of the multi-modality treatment of children and adolescents with metastatic rhabdomyosarcoma (RMS) or non-rhabdomyosarcoma soft tissue sarcoma (NRSTS). Patients and methods Eligible patients aged ≥6 months to <18 years were randomised to receive induction chemotherapy (four cycles of IVADo + five cycles of IVA, ±bevacizumab), surgery and/or radiotherapy, followed by maintenance chemotherapy (12 cycles of low-dose cyclophosphamide + vinorelbine, ±bevacizumab). The primary objective was event-free survival (EFS) evaluated by an independent radiological review committee. Results One hundred and fifty-four patients were randomised to receive chemotherapy alone (n = 80) or with bevacizumab (n = 74). At the data cut-off for the primary efficacy analysis, median EFS was 14.9 months (95% confidence interval [CI]: 10.8–35.9) with chemotherapy and 20.6 months (95% CI: 15.2–24.9) with bevacizumab plus chemotherapy (stratified hazard ratio [HR] = 0.93; 95% CI: 0.61–1.41; P = 0.72). The HR for EFS in patients with RMS (n = 103) was 1.24 (95% CI: 0.73–2.09) versus 0.64 (95% CI: 0.32–1.26) for those with NRSTS (n = 49). Objective response rate was 36.0% (95% CI: 25.2–47.9) with chemotherapy and 54.0% (95% CI: 40.9–66.6) with bevacizumab plus chemotherapy (difference of 18.0%; 95% CI: 0.6–35.3). There were no treatment-related deaths and no increased incidence of grade 3/4 toxicities with bevacizumab. Conclusion The addition of bevacizumab to chemotherapy appeared tolerable in children and adolescents with metastatic RMS/NRSTS, but the primary end-point of EFS did not show statistically significant improvement. Trial registration: ClinicalTrials.gov, NCT00643565.
科研通智能强力驱动
Strongly Powered by AbleSci AI